is preparing to launch a Phase 3 study of its Covid-19 vaccine in July, the company’s CEO said there is a high probability that the company’s product could reach distribution in 2021.
“It seems to be possible that we could have data on effectiveness through, say, Thanksgiving,” Moderna (ticker: ARNM) chief executive officer Stéphane Bancel, said during the meeting. The Barron’s Investing in Technology conference Wednesday. Whether the data would potentially allow Moderna to fight for approval at the end of this year or the start of the new year, Bancel said.
As The barron’s Previously reported, Moderna is one of several companies using relatively new technology to create a Covid-19 vaccine. FDA approval of the technology, which uses synthetic messenger ribonucleic acid, or RNA, to create a protein that causes an immune response, could pave the way for the rest of the pipeline company.
Bancel said the company’s experience creating vaccines is partly responsible for the speed of the Moderna Covid-19 vaccine candidate. “In fact, it was the 10th vaccine we put to the clinical trial,” Bancel said. “We have learned a lot over the years: how to optimize the manufacturing process, how to optimize your chemistry, to get the best vaccine we could.”
The vaccine against the clinical and manufacturing plans addressed, Moderna is now working with several groups to determine the vaccine of economic value and how much of an action of this value that society thinks is right for the capture, Bancel said. “We need to make sure that the vaccine is affordable, so that everyone can be vaccinated, either because it is paid for by a private payer or by the government.”
While Moderna is far from the only company working to produce a Covid-19 vaccine from mid-May, there were more than 100 vaccination programs underway — Bancel said it doesn’t see the other vaccine companies efforts as negative. “There is not a single company in the world that has the capacity to produce the world’s supply,” he said, adding his belief that many vaccines will ultimately be approved. “And we need it because we have to vaccinate a lot of people to stop this public health emergency.”
E-mail: Shaina Mishkin at [email protected]